MX2021015873A - Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1. - Google Patents
Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1.Info
- Publication number
- MX2021015873A MX2021015873A MX2021015873A MX2021015873A MX2021015873A MX 2021015873 A MX2021015873 A MX 2021015873A MX 2021015873 A MX2021015873 A MX 2021015873A MX 2021015873 A MX2021015873 A MX 2021015873A MX 2021015873 A MX2021015873 A MX 2021015873A
- Authority
- MX
- Mexico
- Prior art keywords
- positive allosteric
- allosteric modulator
- tetrahydroisoquinoline derivative
- substituted tetrahydroisoquinoline
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a un compuesto de acuerdo con la fórmula (I), (ver Fórmula) que es un modulador alostérico positivo de D1 y, en consecuencia, es beneficioso como agente farmacéutico para el tratamiento de enfermedades en las cuales los receptores D1 juegan un papel.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19183643 | 2019-07-01 | ||
| PCT/EP2020/068183 WO2021001288A1 (en) | 2019-07-01 | 2020-06-29 | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021015873A true MX2021015873A (es) | 2022-02-03 |
Family
ID=67137843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021015873A MX2021015873A (es) | 2019-07-01 | 2020-06-29 | Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20220259179A1 (es) |
| EP (1) | EP3993794A1 (es) |
| JP (1) | JP2022539152A (es) |
| KR (1) | KR20220029686A (es) |
| CN (2) | CN113993857B (es) |
| AR (1) | AR119318A1 (es) |
| AU (1) | AU2020299953A1 (es) |
| BR (1) | BR112021022378A2 (es) |
| CA (1) | CA3139571A1 (es) |
| CL (1) | CL2021002946A1 (es) |
| CO (1) | CO2021018155A2 (es) |
| EC (1) | ECSP21093559A (es) |
| IL (1) | IL289314A (es) |
| MA (1) | MA56440A (es) |
| MX (1) | MX2021015873A (es) |
| PE (1) | PE20221020A1 (es) |
| SG (1) | SG11202112537YA (es) |
| TW (1) | TW202115010A (es) |
| WO (1) | WO2021001288A1 (es) |
| ZA (1) | ZA202109193B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022129268A1 (en) | 2020-12-18 | 2022-06-23 | UCB Biopharma SRL | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
| MX2023007154A (es) | 2020-12-18 | 2023-06-28 | UCB Biopharma SRL | Dispersiones solidas amorfas. |
| EP4263519A1 (en) | 2020-12-18 | 2023-10-25 | UCB Biopharma SRL | Prodrugs of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]ethanone |
| US20240165101A1 (en) * | 2021-03-09 | 2024-05-23 | Eli Lilly And Company | Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2125741A1 (en) | 2007-03-01 | 2009-12-02 | Janssen Pharmaceutica, N.V. | Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor |
| KR101284796B1 (ko) | 2011-10-05 | 2013-07-10 | (주)포인트엔지니어링 | 캔 패지키 타입의 광 디바이스 제조 방법 및 이에 의해 제조된 광 디바이스 |
| JO3316B1 (ar) | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
| WO2016055479A1 (en) | 2014-10-08 | 2016-04-14 | Ucb Biopharma Sprl | Tetrahydroisoquinoline derivatives |
| EA036137B1 (ru) * | 2016-04-13 | 2020-10-02 | Юсб Байофарма Спрл | Производные тетрагидроизохинолина |
| TWI725408B (zh) | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | 多巴胺d1受體正向異位調節劑 |
-
2020
- 2020-06-29 MX MX2021015873A patent/MX2021015873A/es unknown
- 2020-06-29 AU AU2020299953A patent/AU2020299953A1/en active Pending
- 2020-06-29 CN CN202080043657.XA patent/CN113993857B/zh active Active
- 2020-06-29 PE PE2021002218A patent/PE20221020A1/es unknown
- 2020-06-29 JP JP2021577411A patent/JP2022539152A/ja active Pending
- 2020-06-29 SG SG11202112537YA patent/SG11202112537YA/en unknown
- 2020-06-29 WO PCT/EP2020/068183 patent/WO2021001288A1/en active Application Filing
- 2020-06-29 MA MA056440A patent/MA56440A/fr unknown
- 2020-06-29 CA CA3139571A patent/CA3139571A1/en active Pending
- 2020-06-29 KR KR1020227002600A patent/KR20220029686A/ko active Search and Examination
- 2020-06-29 EP EP20734406.0A patent/EP3993794A1/en active Pending
- 2020-06-29 BR BR112021022378A patent/BR112021022378A2/pt unknown
- 2020-06-29 CN CN202311788931.8A patent/CN117700395A/zh active Pending
- 2020-06-29 US US17/621,851 patent/US20220259179A1/en active Pending
- 2020-06-30 TW TW109122035A patent/TW202115010A/zh unknown
- 2020-06-30 AR ARP200101853A patent/AR119318A1/es unknown
-
2021
- 2021-11-08 CL CL2021002946A patent/CL2021002946A1/es unknown
- 2021-11-17 ZA ZA2021/09193A patent/ZA202109193B/en unknown
- 2021-12-23 IL IL289314A patent/IL289314A/en unknown
- 2021-12-29 EC ECSENADI202193559A patent/ECSP21093559A/es unknown
- 2021-12-29 CO CONC2021/0018155A patent/CO2021018155A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021001288A1 (en) | 2021-01-07 |
| US20220259179A1 (en) | 2022-08-18 |
| ZA202109193B (en) | 2023-11-29 |
| IL289314A (en) | 2022-02-01 |
| CO2021018155A2 (es) | 2022-01-17 |
| EP3993794A1 (en) | 2022-05-11 |
| BR112021022378A2 (pt) | 2022-03-08 |
| CN113993857A (zh) | 2022-01-28 |
| CN117700395A (zh) | 2024-03-15 |
| MA56440A (fr) | 2022-05-11 |
| TW202115010A (zh) | 2021-04-16 |
| ECSP21093559A (es) | 2022-02-25 |
| AR119318A1 (es) | 2021-12-09 |
| WO2021001288A9 (en) | 2021-09-02 |
| AU2020299953A1 (en) | 2022-01-06 |
| JP2022539152A (ja) | 2022-09-07 |
| CA3139571A1 (en) | 2021-01-07 |
| CN113993857B (zh) | 2024-01-02 |
| PE20221020A1 (es) | 2022-06-16 |
| KR20220029686A (ko) | 2022-03-08 |
| CL2021002946A1 (es) | 2022-07-15 |
| SG11202112537YA (en) | 2021-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021006421A (es) | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). | |
| ZA202109193B (en) | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| TN2018000043A1 (en) | Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors | |
| MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
| MX2016013529A (es) | Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos. | |
| MX363127B (es) | Derivados de benzotiofeno como inhibidores del receptor de estrogeno. | |
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| MX2017010735A (es) | Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta). | |
| TN2015000391A1 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| TN2012000421A1 (en) | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents | |
| EA201592255A1 (ru) | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания | |
| PH12020552017A1 (en) | 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof | |
| MX358961B (es) | Compuestos de tetraciclina sustituidos con fluor en c7. | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| IN2012DN02502A (es) | ||
| MX364400B (es) | Compuestos de tetraciclina. | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| EA201692300A1 (ru) | Производные карбоксамида | |
| EA202091604A1 (ru) | Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом | |
| IN2014DN05972A (es) | ||
| CR20220538A (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
| MY195576A (en) | Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof | |
| MX2021009971A (es) | Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos. | |
| MX2022007171A (es) | Compuestos cíclicos y métodos de uso de estos. |